ライフサイエンスコーパス: S1P receptor

1 S1P4 GPCRs as the only functionally relevant S1P receptor.

2 lular signaling mediated by a single type of S1P receptor.

3 as a key downstream effector of the BCR and S1P receptors.

4 ates vascular and immune cells by activating S1P receptors.

5 ar face of the third transmembrane domain of S1P receptors.

6 stimulating SK1-dependent transactivation of S1P receptors.

7 720, an immunosuppressant that downmodulates S1P receptors.

8 n, suggesting the requirement for Gi-coupled S1P receptors.

9 finity agonists of at least four of the five S1P receptors.

10 ediated by intracellular S1P, independent of S1P receptors.

11 t can amplify MC responses by binding to its S1P receptors.

12 by approximately 12-fold, independent of the S1P receptors.

13 dro-S1P, which is active at all cell surface S1P receptors.

14 tic for a family of sphingosine-1-phosphate (S1P) receptors.

15 and interacts with sphingosine-1-phosphate (S1P) receptors.

16 okine receptors and sphingosine-1-phosphate (S1P) receptors.

17 r of the five known sphingosine-1-phosphate (S1P) receptors.

18 ffinity agonist for sphingosine 1-phosphate (S1P) receptors.

19 g as an agonist for sphingosine-1-phosphate (S1P) receptors.

20 a full agonist for sphingosine-1-phosphate (S1P) receptors.

21 ough CCR7, CCR2, and sphingosine-1-phospate (S1P) receptors.

22 phosphorylation of the C-terminal domain of S1P receptor 1 (S1P(1)) at multiple sites, resulting in

23 ell egress from lymphoid organs by acting on S1P receptor 1 (S1P(1)R).

24 eceptors CCR7 and CXCR4 concomitant with low S1P receptor 1 (S1P1) expression.

25 Here, we report that the S1P receptor 1 (S1P1) is expressed in neuroblasts migrat

26 ) deficiency or by selective agonists of the S1P receptor 1 (S1P1), indicating that PAR1 signaling co

27 to FTY720, we saw a significant increase in S1P receptor 1 (S1P1)-expressing CD68+ macrophages in su

28 We found that genetic deletion of the S1P receptor 1 (S1pr1) alone in CD11b(hi) CD206(+) TAMs

29 d by acute treatment with an agonist for the S1P receptor 1 (S1pr1).

30 Only depletion of S1P receptor 1 abrogated the effects of dhS1P and S1P in

31 SSc fibroblasts, which had reduced levels of S1P receptor 1 and S1P receptor 2 and elevated levels of

32 es with either S1P or a selective agonist of S1P receptor 1 enhanced bacterial colocalisation with LA

33 te (S1P) signaling via the G protein-coupled S1P receptor 1 in these progenitors.

34 In contrast, depletion of either S1P receptor 1 or S1P receptor 2 prevented the effects o

35 Marginal zone B cells expressed S1P receptors 1 and 3 (S1P(1) and S1P(3), respectively).

36 lipid sphingosine 1-phosphate (S1P), through S1P receptors 1 and 3 (S1P1/S1P3), and VEGF receptor 2 (

37 cells were less evident and eNOS, iNOS, and S1P receptors 1 and 3 were up-regulated in aortas from m

38 dy, we identify the sphingosine 1-phosphate (S1P) receptor 1 (S1P1) as one of the key players that go

39 an immunomodulatory sphingosine-1-phosphate (S1P) receptor 1 (S1P1R) agonist significantly inhibited

40 Sphingosine-1-phosphate (S1P) receptor 1 (S1PR1) is critical for lymphocyte egres

41 he egress receptor, sphingosine-1-phosphate (S1P) receptor 1 (S1PR1), was expressed at low levels in

42 tic significance of sphingosine 1-phosphate (S1P) receptors 1, 2, and 3 (ie, S1P1, S1P2, and S1P3), S

43 S1P receptors (1-5) and S1P-metabolizing enzymes were ex

44 e a mechanism by which the G protein-coupled S1P receptor-1 (S1P1) stabilizes the primary vascular ne

45 ase-2 (GRK2) functions in down-regulation of S1P receptor-1 (S1PR1) on blood-exposed lymphocytes.

46 sphate (S1P) and the regulated expression of S1P receptor-1 (S1PR1), we investigated whether the expr

47 ing RNA that targets sphingosine kinase-1 or S1P receptor-1 blocked this protective signaling by APC.

48 S1P receptor-1 is required for lymphocyte egress from th

49 er-disruptive PAR1 pathway, and suggest that S1P receptor-1 mediates protective effects of APC in sys

50 The sphingosine 1-phosphate (S1P) receptor-1 (S1P(1)) is required for stabilization o

51 FTY720 or that lack sphingosine-1-phosphate (S1P) receptor-1 (S1P1) in B cells, IgG ASCs are induced

52 he cardioprotective sphingosine-1-phosphate (S1P) receptor-1 (S1PR1).

53 d organs depends on sphingosine 1-phosphate (S1P) receptor-1 and is thought to occur in response to c

54 Lymphocytes require sphingosine-1-phosphate (S1P) receptor-1 to exit lymphoid organs, but the source(

55 role of endothelial sphingosine 1-phosphate (S1P) receptor-1, a G protein-coupled receptor known to p

56 signaling is a plausible mechanism by which S1P-receptor-1 agonists function as immunosuppressives.

57 und that Th17 cells egress from the gut in a S1P-receptor-1-dependent fashion and subsequently migrat

58 the rescue required lymphocyte expression of S1P-receptor-1.

59 the endothelial differentiation gene family (S1P receptors-(1-5)).

60 were abolished following administration of a S1P receptor 2 (S1P2) antagonist or a PI3K inhibitor.

61 ion of Bcr-Abl1 by SK-1/S1P was dependent on S1P receptor 2 (S1P2) signaling, which prevented Bcr-Abl

62 a pharmacologic SphK inhibitor (SKI2), and a S1P receptor 2 (S1PR2) antagonist (JTE013) were used in

63 Conversely, S1P receptor 2 (S1PR2), which antagonizes migration towa

64 ich had reduced levels of S1P receptor 1 and S1P receptor 2 and elevated levels of S1P receptor 3.

65 BH3 mimetics with either SPHK1 inhibition or S1P receptor 2 antagonism triggered synergistic AML cell

66 trast, depletion of either S1P receptor 1 or S1P receptor 2 prevented the effects of S1P and dhS1P in

67 ociated with reduced survival signaling from S1P receptor 2, resulting in selective downregulation of

68 f FAK and invasion, and this was mediated by S1P receptor 2.

69 phingosine kinase 1 (SphK1) or antagonism of S1P receptors 2 and 4 (S1P2/4).

70 tion was induced in sphingosine 1-phosphate (S1P) receptor 2 (S1P2)-null and wild-type mice by ligati

71 ng mutations in the sphingosine-1-phosphate (S1P) receptor 2 (S1PR2) promoter have been associated wi

72 by combining chemical and genetic probes for S1P receptor 3 (S1P3) we show a critical role for dendri

73 FTY720 triggers MDSCs to release GM-CSF via S1P receptor 3 (S1pr3) through Rho kinase and extracellu

74 ination (metastasis) of melanoma cells via a S1P receptor 3-mediated mechanism.

75 endothelial transmigration by activating the S1P receptor 3.

76 1 and S1P receptor 2 and elevated levels of S1P receptor 3.

77 osine-1-phosphate (S1P) gradients, sensed by S1P receptor 5 (S1P5).

78 n of S1P on sickling that was independent of S1P receptor activation in isolated erythrocytes.

79 S1P transporter spinster homolog 2 (SPNS2), S1P receptor activation, JAK2/STAT3-dependent miR-181b-1

80 ve response of glial cells to PAR-1, LPA, or S1P receptor activation, suggesting that each of these p

81 dies represent the first characterization of S1P receptor activity through G proteins directly and es

82 id cyclohexane ring without compromising the S1P receptor affinity profile of these novel compounds.

83 s for rapidly regulating thymic export where S1P receptor agonism alters both phenotypic maturation a

84 augmentation of Th17 cell development by the S1P receptor agonist and down-regulator FTY720 implies t

85 harmacologic treatment with the nonselective S1P receptor agonist FTY720 causes increased bone format

86 Treatment with the S1P receptor agonist FTY720 emptied the cortical sinusoi

87 f phagocytes within peripheral LNs using the S1P receptor agonist FTY720 or S1P1-specific agonist SEW

88 Indeed, an S1P receptor agonist is undergoing clinical trials to co

89 of fingolimod was found to be a nonselective S1P receptor agonist, agonism specifically of S1P1 is re

90 In particular, FTY720, a pan-S1P receptor agonist, has been efficacious in the treatm

91 The sphingosine-1-phosphate (S1P) receptor agonist fingolimod (FTY720), that has show

92 mod, a nonselective sphingosine-1-phosphate (S1P) receptor agonist that induces sustained lymphopenia

93 ) is a nonselective sphingosine-1-phosphate (S1P) receptor agonist thought to be devoid of activity a

94 The sphingosine-1-phosphate (S1P) receptor agonist, phosphorylated FTY720 (FTY-P), ca

95 ch acts as a potent sphingosine-1-phosphate (S1P) receptor agonist.

96 of CD69 induced by sphingosine 1-phosphate (S1P) receptor agonist.

97 The S1P receptor agonists FTY720 and FTY720-phosphate and th

98 S1P receptor agonists induced emptying of lymphoid sinus

99 this model to work examining the effects of S1P receptor agonists on endothelium.

100 of lymphocyte recirculation by non-selective S1P receptor agonists produces clinical immunosuppressio

101 The recent development of S1P receptor agonists, led by the immunomodulatory pro-d

102 e MLN cells harvested from mice treated with S1P receptor agonists, we saw a redistribution of lympho

103 Sphingosine-1-phosphate (S1P) receptor agonists are novel immunosuppressive agent

104 Dihydro-S1P, which binds to S1P receptors, also stimulated contractility.

105 ed mutations affecting genes that encode the S1P receptor and 2 small GTPases (GNA13 and GNAI2) that

106 phingolipid that activates G protein-coupled S1P receptors and initiates a broad range of responses i

107 rstanding of how FTY720, a drug that targets S1P receptors and is approved for the treatment of multi

108 Here, we report that the S1P receptors and metabolic enzymes are conserved in the

109 S1P receptors and metabolizing enzymes have been deleted

110 lecule for studying the molecular biology of S1P receptors and related enzymes (kinases and phosphata

111 n effect and that cell origin determines the S1P receptors and signaling routes involved.

112 on of S1P, which leads to transactivation of S1P receptors and their downstream signaling pathways, r

113 functions through extracellular ligation to S1P receptors, and it also functions as an intracellular

114 There are 5 known S1P receptors, and S1P induces adherens junction formati

115 S1P signaling and provide leads for further S1P receptor antagonist development.

116 Recently, a pharmacological S1P receptor antagonist has won approval to control auto

117 which was partially rescued by VPC23109, an S1P receptor antagonist.

118 S1P receptor antagonists failed to prevent histamine-ind

119 ed arteries using native and S1P-loaded HDL, S1P receptor antagonists, and S1P-blocking antibodies.

120 Subtype-specific S1P receptor antibodies revealed that the expression of

121 S1P receptors are a highly promising target in stroke tr

122 Various S1P receptors are present in the cardiovascular system,

123 Because S1P receptors are therapeutically interesting, identifyi

124 Sphingosine-1-phosphate (S1P) receptors are critical for lymphocyte egress from s

125 been shown that the sphingosine 1 phosphate (S1P) receptors are the direct molecular targets of FTY72

126 pertussis toxin, an inhibitor of Gi-coupled S1P receptors, as well as antagonists of the S1P recepto

127 we show for the first time that the S1P/SPL/S1P-receptor axis regulates the expression of a number o

128 ot mediated through cell surface Gi -coupled S1P receptors, because none of these responses were inhi

129 mil encodes Edg5, a sphingosine-1-phosphate (S1P) receptor belonging to a family of five G-protein-co

130 Recent information on S1P receptor biology suggests potential utility in the c

131 nduced colocalization of S1P(1) (promotility S1P receptor) but not S1P(2), with SphK1 and FLNa at mem

132 show that functional antagonism of vascular S1P receptors by FTY720 potently inhibits angiogenesis;

133 Thus, differential transactivation of S1P receptors by NGF regulates antagonistic signaling pa

134 desensitization of Sphingosine-1-phosphate (S1P) receptors by FTY720 as well as disruption of S1P gr

135 Although S1P receptors can regulate lymphoid development and lymp

136 sychoactive ingredient in marijuana, whereas S1P receptors contribute to the immunosuppressant effect

137 vity on S1P1 while sparing activity on other S1P receptors could offer equivalent efficacy with reduc

138 aberrant S1P receptor signaling, and lack of S1P receptor coupling to G proteins.

139 human umbilical vein endothelial cells in a S1P receptor-dependent manner.

140 t that a complex interplay between PDGFR and S1P receptors determines their functions.

141 The distribution and function of S1P receptors differ in SSc and healthy fibroblasts, sug

142 the expression of S1P regulatory enzymes and S1P receptors during cardiac development.

143 hepatoma cells stably transfected with human S1P receptor Edg3 or Edg5, which was attributable to sti

144 ist) and dihydro-S1P (potent agonist for all S1P receptors except S1P2) were poor contractile agents.

145 FTY720-P, an S1P analogue that binds all S1P receptors except S1P2, did not inhibit glioblastoma

146 ressant FTY720-phosphate, an agonist for all S1P receptors except S1P2, had distinct contractile prop

147 tiation gene family sphingosine 1-phosphate (S1P) receptors except S1P receptor subtype 2 (S1P(2)).

148 We conclude that S1P receptors expressed by neuroglia are involved in reg

149 e expression of the sphingosine-1-phosphate (S1P) receptors expressed by MZ B cells and/or increased

150 We also demonstrate that S1P receptor expression is deregulated in primary OSCCs

151 Modulation of S1P receptor expression profiles, and of enzymes involve

152 he present study, the effects of S1P and EDG/S1P receptor expression were determined in rat VSM from

153 Given the ubiquity of SK and S1P receptor expression, S1P receptor transactivation ma

154 Activation of CD4 T cells, which decreases S1P receptor expression, suppressed effects of S1P on ch

155 Many of the S1P effects are mediated through S1P receptor family members (S1P(1-5)).

156 igand for G-protein-coupled receptors of the S1P receptor family, regulating diverse biological proce

157 Immunoprecipitation of S1P receptors from CEM fractions revealed complexes cont

158 ycling to the cell surface, and desensitized S1P receptor function.

159 0 was independent of its phosphorylation and S1P receptor functions.

160 membrane-associated SphK1 activity, restored S1P receptor functions.

161 ussis toxin (PTX) treatment, consistent with S1P receptor/G(i) protein coupling.

162 re we show that the sphingosine-1-phosphate (S1P) receptor Gpr6 is selectively expressed in the stria

163 The S1P receptors have a novel N-terminal fold that occludes

164 Five S1P receptors have been identified in mammals: LP(B1)/ED

165 ory functions in the apparent absence of EDG S1P receptor homologues.

166 e involved in activating a G protein-coupled S1P receptor important for EGF-directed migration.

167 e also showed that S1P(5) is the predominant S1P receptor in leukemic LGLs, whereas S1P(1) is down-re

168 of this study was to investigate the role of S1P receptors in a non-T-cell model of demyelination, th

169 However, the role of S1P receptors in normal immune cell trafficking is uncle

170 cells (VSMCs), the functions of the specific S1P receptors in the latter cell type are not known.

171 S1P receptors in the vascular system have been character

172 Modulation of sphingosine 1-phosphate (S1P) receptors in a non-selective manner decreases disea

173 ion and function of sphingosine-1-phosphate (S1P) receptors in human thymocyte egress.

174 d/or S1P may regulate calcium channels in an S1P receptor-independent manner.

175 S1P exerts its effects in S1P receptor-independent manner.

176 Structural modeling of the S1P receptors indicated that only S1P(2) can accommodate

177 signaling pathways of glial PAR-1, LPA, and S1P receptors indicates that each receptor class activat

178 Small molecule drugs that downregulate S1P receptors induce the sequestration of lymphocytes wi

179 a drug that targets sphingosine 1-phosphate (S1P) receptors, induced marginal zone B cell migration i

180 Recently, the sphingosine-1-phosphate (S1P) receptor inhibitor FTY720 (also known as Fingolimod

181 and confocal microscopy were used to detect S1P receptors, interleukin (IL) 1R, IL17RA, and nitrosat

182 s, we found that IGF-1 and IGF-2 induced GFP-S1P receptor internalization and that the effect was blo

183 sponding glutamate residue, conserved in all S1P receptors, ion pairs with the S1P ammonium.

184 The expression and localization of S1P receptors is dynamically regulated and controls vasc

185 Distribution of S1P receptor isoforms was altered in SSc fibroblasts, wh

186 sing mouse embryonic fibroblasts (MEFs) from S1P receptor knockout mice, we show here that S1P3 was r

187 20, is a ligand for sphingosine 1-phosphate (S1P) receptors led to studies demonstrating that S1P rec

188 Bioinformatic analysis identified seven S1P receptor-like sequences in the zebrafish genome, inc

189 G2 transporters and consequent activation of S1P receptors may contribute to nongenomic signaling of

190 of lymphocyte recirculation by activation of S1P receptors may result in therapeutically useful immun

191 Mutations in the zebrafish gene encoding the S1P receptor Miles Apart (Mil)/S1P(2) disrupt the format

192 the spleen and bone marrow, suggesting that S1P receptor modulation restricts egress from hematopoie

193 lation of AAL-R and sphingosine 1-phosphate (S1P) receptor modulation in lungs is essential for immun

194 he safety and efficacy of the oral selective S1P receptor modulator ozanimod in patients with relapsi

195 limod (FTY720) is a sphingosine 1-phosphate (S1P) receptor modulator that regulates lymphocyte traffi

196 ration of FTY720, a sphingosine 1-phosphate (S1P) receptor modulator, to db/db mice normalizes fastin

197 h in naive and inflammatory conditions, with S1P receptor modulators FTY720 and BAF312.

198 ional insights on the mechanism of action of S1P receptor modulators in disease.

199 We demonstrate that S1P receptor modulators reduce circulating monocytes in

200 e egress from secondary lymphoid organs, and S1P receptor modulators suppress lymphocyte circulation.

201 receptors, we examined embryos with multiple S1P receptor mutations.

202 The sustained bradycardia induced by S1P receptor non-selective immunosuppressive agonists in

203 tely prevented ERK1/2 activation mediated by S1P receptors, not only reduced migration toward S1P but

204 However, multiple leukocyte subsets express S1P receptors of varying types, and although it is benef

205 S1P-R1 was the prevalent S1P receptor on mature human thymocytes (CD3(hi)CD27(+)C

206 as well as for the biologic functions of the S1P receptors on cells that are circulating in the blood

207 These data reveal a novel role for S1P receptors on monocytes and offer additional insights

208 However, the role of S1P receptors on monocytes is less clear.

209 duced internalization and desensitization of S1P receptors on the surface of mast cells as determined

210 LPA) receptors, and sphingosine-1-phosphate (S1P) receptors on murine astrocytes.

211 alogs induce immunosuppression by modulating S1P receptors other than S1P(1) or S1P(2) on dendritic c

212 The interaction of S1P with the S1P receptors plays a fundamental physiological role in

213 lts highlight the relevance of chemokine and S1P receptor recycling in CLL pathogenesis and clinical

214 , which suggests that discrete mechanisms of S1P receptor regulation are responsible for the efficacy

215 study, we show that expression of S1P1, the S1P receptor responsible for lymphocyte egress, is selec

216 SHEP1 association is required for the BCR or S1P receptor(s) to induce the conversion of CasL into it

217 embryo proper, yolk sac, and allantois, the S1P receptor S1P(2) is expressed in conjunction with S1P

218 ell traffic and proliferation through type 1 S1P receptor (S1P(1)) signals, but suppression of IFN-ga

219 Lymphocyte type 1 S1P receptor (S1P(1)) that transduces S1P chemotactic st

220 RT-PCR revealed that four of the five known S1P receptors (S1P(1-4)) are also expressed in the devel

221 We aimed to determine whether S1P receptors (S1P-Rs) play a role in mature human thymo

222 l differential CD44 isoform interaction with S1P receptors, S1P receptor transactivation, and RhoA/Ra

223 ediator through binding to 5 highly specific S1P receptors, S1P(1-5).

224 ma membrane and differentially activates the S1P receptors S1P1 and S1P2 in a SphK1-dependent manner,

225 Although detrusor expresses the S1P receptors S1P1 and S1P2, only S1P2 appeared to be in

226 recruitment (1 microM, 5 min) to CEMs of the S1P receptors S1P1 and S1P3, p110 PI3 kinase alpha and b

227 Cultured NPCs expressed transcripts for S1P receptors S1P1, S1P2, S1P3, S1P4, and S1P5.

228 P) signaling on targeted cells that bear the S1P receptors S1P1, S1P3, S1P4, and S1P5.

229 king, including the sphingosine-1-phosphate (S1P) receptor S1P1, CD62L and beta7 integrin.

230 ice whose haematopoietic cells lack a single S1P receptor (S1P1; also known as Edg1) there are no T c

231 led lpA receptors (LPA1, LPA2, and LPA3) and s1p receptors (S1P1, S1P2, S1P3, S1P4, and S1P5), collec

232 of HDL-S1P are dependent on signaling by the S1P receptor, S1P1, and involve persistent activation of

233 transporter, spinster homolog 2 (Spns2), and S1P receptor, S1P1, in lamellipodia formation and perhap

234 S1P receptors, as well as antagonists of the S1P receptor, S1P1, inhibited barrier enhancement by HDL

235 Although the S1P receptors (S1P1R, S1P2R, and S1P3R) are expressed, p

236 Here, we show that two S1P receptors, S1P2 and S1P3, are collectively essential

237 Two S1P receptors, S1P2 and S1P3, were found to be expressed

238 l phenotype is normalized by deletion of the S1P receptor S1P3.

239 d the induction of fibrotic responses by the S1P receptor (S1PR) agonists S1P, FTY720-P, ponesimod, a

240 This inhibition is mediated by the S1P receptor (S1PR)-2 via an inhibitory G-dependent mech

241 ed the potential of sphingosine 1-phosphate (S1P) receptor (S1PR) agonism in the treatment of infecti

242 Correspondingly, mice lacking the S1P receptor S1pr1 develop severe thrombocytopenia cause

243 1 (SphK1(-/-)) or with reduced expression of S1P receptors (S1PR1(+/-), S1PR2(-/-), and S1PR3(-/-)) e

244 or STAT3, and consequent upregulation of the S1P receptor, S1PR1.

245 Rather, two S1P receptors, S1PR1 and S1PR2, coordinately promoted mi

246 Mice lacking the S1P receptor S1PR2 also showed a delay in plasma histami

247 mediated at least in part by ligation of the S1P receptor, S1PR2.

248 that expression of SPNS2, expression of the S1P receptor S1PR5 on NK cells, and expression of the ch

249 and Gbetagamma subunits, the G proteins that S1P receptors (S1PRs) couple to and signal through.

250 tor of G protein signaling 3, which inhibits S1P receptor signaling and completely prevented ERK1/2 a

251 n many types of neurodegeneration, the Sphk1/S1P receptor signaling axis may be generally important d

252 This work establishes a role for S1P receptor signaling in the local conditioning of tiss

253 ion in S1P lyase-deficient mice, implicating S1P receptor signaling in the phenotype.

254 ocal immunofluorescence microscopy, aberrant S1P receptor signaling, and lack of S1P receptor couplin

255 some key physiologic processes that require S1P receptor signaling, such as vascular development and

256 The sphingosine-1-phosphate (S1P) receptor signaling system has biological and medica

257 The sphingosine 1-phosphate (S1P) receptor signaling system is a productive model sys

258 (iNOS) expression, sphingosine 1 phosphate (S1P) receptor status, and apoptosis.

259 orn that corresponded with the engagement of S1P receptor subtype 1 (S1PR(1))- dependent neuroinflamm

260 hingosine 1-phosphate (S1P) receptors except S1P receptor subtype 2 (S1P(2)).

261 adenocarcinoma cell lines abundantly express S1P receptor subtype 3 (S1P3), thus providing a tractabl

262 ing proteases and selectivity in coupling to S1P receptor subtypes determine vascular PAR1 signaling

263 ignaling may be related to the expression of S1P receptor subtypes.

264 reported expression and in vitro studies of S1P receptors suggested that direct CNS effects of FTY72

265 he action of SK2, with signaling mediated by S1P receptors that include S1P(1), S1P(2), and S1P(3).

266 ed by chemokine and sphingosine 1-phosphate (S1P) receptors that enable homing and egress from second

267 nvironment and signals via G protein-coupled S1P receptors to regulate cell-cell and cell-matrix adhe

268 that extracellular S1P acts through vascular S1P receptors to regulate vascular development.

269 points regulated by constitutive and induced S1P receptor tone at vascular endothelial and lymphatic

270 ubiquity of SK and S1P receptor expression, S1P receptor transactivation may represent a general mec

271 CD44 isoform interaction with S1P receptors, S1P receptor transactivation, and RhoA/Rac1 signaling to

272 receptors led to studies demonstrating that S1P receptor type 1 (S1P1) is needed in T cells and B ce

273 Here we report that sphingosine 1-phosphate (S1P) receptor type 1 (S1P1) delivers an intrinsic negati

274 functions of the two other widely expressed S1P receptors, we generated S1P(2) and S1P(3) null mice.

275 ndent of effects on sphingosine-1-phosphate (S1P) receptors, we embarked on the pharmacological explo

276 The wild-type and mutant S1P receptors were expressed in Chinese hamster ovary ce

277 by RNA interference, and blocking endogenous S1P receptors with the competitive antagonist VPC23019 a

278 Furthermore, activation of S1P receptors with their natural ligand, S1P, as well as